Develop a range of different technical platforms, including autologous and specific homologous antigen receptor T cells, T cell receptor (tcr-t) and natural killer (NK) cell immunotherapy. From our three R & D sites around the world, we apply these innovative technologies to seek safe, effective and cutting-edge choices for patients around the world.
正在翻译中..